Mesolimbic dopaminergic function influences addiction through effects on reinforcement learning, decision-making, and impulsivity. This review covers sex differences in dopaminergic neurochemistry, their hormonal and genetic determinants, and how differences in dopaminergic tone interact with sex and/or ovarian hormone status to affect cognitive functions. Findings from research on cigarette smoking reveal sex differences in striatal and midbrain dopamine D2-type receptor availability and striatal dopamine release that suggest mechanisms of nicotine dependence, and stronger subjective responses to nicotine and efficacy of nicotine replacement therapies in male smokers than in their female counterparts. Opportunities exist to extend such efforts in studies of how sex and hormone status influence other addictions.
Current Opinion in Behavioral Sciences
This review comes from a themed issue on Sex and gender Introduction: sex differences and dopaminergic signaling in drug use disorders
The prevalence, course, and consequences of substance use disorders differ in men and women. Although men are approximately 70% more likely than women to have a substance use disorder, more women than men (12-49 years of age) recently initiated the use of marijuana, stimulants, heroin, phencyclidine, and alcohol [1] . Women tend to escalate from initiation of drug use to addiction more rapidly than men [2, 3] , and are more likely than men to relapse after initiating abstinence [4] . Because substance use increases maternal and perinatal morbidity, women experience addiction-related health consequences that do not affect men [5] . They also are disproportionately affected by other untoward effects of drug use, exhibiting a higher relative risk of smokingrelated cardiovascular disease [6] , and occurrence of cardiovascular [7] and other alcohol-related physical illnesses at lower levels of drinking than men [8] .
The National Institutes of Health now has mandated that sex be considered as a biological variable in all biomedical research [9] , and sex differences have been evaluated in animal models of addiction and human addiction. This review extends previous syntheses of relevant literature [10,11] on sex differences (and in some cases, similarities) in dopaminergic neurochemistry (for review, see [12] ) and addiction. Involvement of dopaminergic systems in the effects of cigarette smoking are highlighted because recent developments and expert recommendations in this research area illustrate an exemplary role for studies of other addictions. Dopaminergic signaling is central to the etiology and maintenance of substance use disorders by influencing the motivational processes underlying the learning and execution of goal-directed behaviors, as indicated by electrophysiological recordings from midbrain dopamine neurons in monkeys [13, 14] . Numerous studies of animal models have implicated striatal dopamine D2-type receptors in vulnerability as well as resilience to addiction [15] [16] [17] [18] [19] [20] [21] [22] . These include findings that striatal D2-type receptor availability influences subsequent cocaine self-administration and that striatal D2-type receptors and dopamine transporters show long-lasting neuroadaptations to stimulant administration in nonhuman primates [23, 24] . Human studies reinforcing this view show below control striatal dopamine D2-type receptor availability in individuals with addictions to various substances, including stimulants, heroin, alcohol, and tobacco (for reviews, see [25, 26] ), and (as detailed below) associations of striatal D2-type receptor availability with cognitive functions that affect addiction.
Dopamine signaling, cognition and responses to drugs: effects of ovarian hormones
Cognitive control and adaptive decision-making, functions that are linked to dopaminergic neurochemical markers, influence the course of addictions [27, 28] . Impaired cognitive control, measured as impulsivity in personality inventories, has been implicated in the initiation, maintenance, and relapse of drug-seeking behaviors [29] . Stimulant users 
